🚨 The FDA has greenlit a first-of-its-kind molecule that helps human immune cells target and destroy cancer cells naturally. In a significant leap forward for cancer immunotherapy, the FDA has cleared a clinical trial for GTB-5550, an investigational drug designed to mobilize the body's innate immune system against blood cancer. Developed by GT Biopharma, this innovative therapy utilizes a proprietary platform known as TriKE (Tri-specific Killer Engager). Unlike traditional treatments, this single molecule performs three critical tasks simultaneously: it anchors to a specific protein on the cancer cell, binds to an activating receptor on the patient's natural killer (NK) cells to form an immunological bridge, and delivers a vital immune-signaling protein that forces those killer cells to multiply and sustain their attack. This regulatory milestone specifically targets multiple myeloma, a bone marrow cancer that remains notoriously difficult to cure and highly prone to relapse. By leveraging NK cells—part of the innate immune system that can rapidly destroy diseased cells without prior priming—this therapy offers a promising alternative to complex, personalized treatments like CAR-T. Because the drug can be administered subcutaneously and acts as an 'off-the-shelf' solution, researchers hope it will bypass the severe side effects and production delays that often limit existing cell therapies, bringing a highly accessible, powerful new weapon to patients who have exhausted other options. source: GT Biopharma, Inc. (2026). GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma. GlobeNewswire.